Introduction {#sec1}
============

Colorectal cancer (CRC) refers to malignancy that occurs in the colon and rectum. It is the third most commonly seen cancer in men, and the second commonly seen cancer in women \[[@B1]\]. Despite rapid advances in early diagnosis and surgical treatment over the past few decades, CRC still accounts for approximately one-tenth of cancer-related deaths, making it one of the major threats to public health worldwide \[[@B2]\]. To date, the exact cause of CRC remains unclear. Although smoking, excessive alcohol intake and high consumption of red meat were already identified as potential risk factors of CRC \[[@B3]\]. The fact that a significant portion of CRC patients did not expose to any of these carcinogenic factors suggests that genetic susceptibility may play a crucial part in the pathogenesis of CRC \[[@B6]\].

Tumor necrosis factor-α (TNF-α) plays a central role in the regulation of anti-tumor immune responses. Previous clinical investigations showed that serum TNF-α levels in CRC patients were significantly elevated \[[@B7]\], and patients with lower TNF-α levels had better prognosis compared with these with higher TNF-α levels \[[@B8],[@B9]\]. Consequently, functional *TNF-α* polymorphisms were thought to be ideal candidate genetic markers of CRC. Recently, some pilot studies were conducted to investigate associations between *TNF-α* polymorphisms and the risk of CRC. But the results of these studies were conflicting \[[@B10]\]. Therefore, we conducted this meta-analysis to better analyze the roles of *TNF-α* polymorphisms in the development of CRC.

Materials and methods {#sec2}
=====================

Literature search and inclusion criteria {#sec2-1}
----------------------------------------

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline \[[@B32]\]. Potentially eligible articles were searched in PubMed, Medline, Embase and CNKI using the combination of following key words: 'tumor necrosis factor-α', 'TNF-α', 'polymorphism', 'variant', 'mutation', 'genotype', 'allele', 'colorectal', 'colon', 'rectal', 'cancer', 'tumor', 'carcinoma', 'neoplasm' and 'malignancy'. The initial literature search was conducted in 2018 February and the latest update was performed in 2018 July. The reference lists of all retrieved publications were also screened to identify other potentially relevant articles.

Included studies should meet all the following criteria: (1) case--control study on correlations between *TNF-α* polymorphisms and the risk of CRC; (2) provide adequate data to calculate odds ratios (ORs) and 95% confidence intervals (CIs); (3) full text available. Studies were excluded if one of the following criteria was fulfilled: (1) not relevant to *TNF-α* polymorphisms and CRC; (2) family-based association studies; (3) case reports or case series; (4) abstracts, reviews, comments, letters and conference presentations. For duplicate reports, only the study with the largest sample size was included. No language restrictions were imposed in this meta-analysis.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

The following data were extracted from included studies: (1) name of the first author; (2) year of publication; (3) country and ethnicity of participants; (4) the number of cases and controls and (5) genotypic distributions of *TNF-α* polymorphisms in cases and controls. Additionally, the probability value (*P* value) of Hardy--Weinberg equilibrium (HWE) test was also calculated based on genotypic frequency of *TNF-α* polymorphisms in the control group.

The Newcastle--Ottawa scale (NOS) was employed to assess the quality of eligible studies from three aspects: (1) selection of cases and controls; (2) comparability between cases and controls and (3) exposure in cases and controls \[[@B33]\]. The NOS has a score range of zero to nine, and studies with a score of more than seven were thought to be of high quality.

Two reviewers (Huang and Qin) conducted data extraction and quality assessment independently. When necessary, the reviewers wrote to the corresponding authors for extra information or raw data. Any disagreement between two reviewers was solved by discussion with the third reviewer (Jiang) until a consensus was reached.

Statistical analyses {#sec2-3}
--------------------

All statistical analyses in the present study were conducted with Review Manager Version 5.3.3 (The Cochrane Collaboration, Software Update, Oxford, United Kingdom). ORs and 95% CIs were used to assess potential associations of *TNF-α* polymorphisms with the risk of CRC in the dominant, recessive, overdominant and allele models, and a *P* value of 0.05 or less was considered to be statistically significant. Between-study heterogeneity was evaluated based on *Q* test and *I*^2^ statistic. If *P* value of *Q* test was less than 0.1 or *I*^2^ was greater than 50%, random-effect models (REMs) would be used for analyses due to the existence of significant heterogeneities. Otherwise, fixed-effect models (FEMs) would be applied for analyses. Subgroup analyses by ethnicity of participants were subsequently conducted to obtain more specific results. Sensitivity analyses were carried out to test the stability of the results. Funnel plots were applied to evaluate possible publication bias.

Results {#sec3}
=======

Characteristics of included studies {#sec3-1}
-----------------------------------

The literature search identified 389 potentially relevant articles. After exclusion of irrelevant and duplicate articles by reading titles and abstracts, 42 articles were retrieved for further evaluation. Another 20 articles were subsequently excluded after reading the full text. Finally, a total of 22 eligible studies were included in this meta-analysis (see [Figure 1](#F1){ref-type="fig"}). Characteristics of included studies were summarized in [Table 1](#T1){ref-type="table"}.

![Flowchart of study selection for the present study](bsr-39-bsr20181750-g1){#F1}

###### The characteristics of included studies for *TNF-α* polymorphisms and CRC

  First author, year                  Country        Ethnicity   Source of controls   Sample size   Genotype distribution   *P*-value for HWE   NOS score   
  ----------------------------------- -------------- ----------- -------------------- ------------- ----------------------- ------------------- ----------- ---
  **-238 G/A**                                                                                      GG/GA/AA                                                
  Garrity-Park 2008 \[[@B13]\]        USA            Mixed       HB                   114/114       109/5/0                 107/6/1             0.017       8
  Gutiérrez-Hurtado 2016 \[[@B15]\]   Mexico         Mixed       PB                   143/49        127/14/2                42/6/1              0.199       7
  Hamadien 2016 \[[@B16]\]            Saudi Arabia   Caucasian   PB                   100/100       86/13/1                 97/2/1              \<0.001     8
  Jang 2001 \[[@B17]\]                Korea          Asian       PB                   27/92         27/0/0                  80/11/1             0.391       8
  Kapitanović 2014 \[[@B18]\]         Croatia        Caucasian   PB                   200/200       181/18/1                188/11/1            0.076       8
  Madani 2008 \[[@B24]\]              Iran           Caucasian   PB                   51/46         51/0/0                  45/1/0              0.941       7
  Wang 2008 \[[@B31]\]                China          Asian       PB                   343/670       320/22/1                620/50/0            0.316       8
  **-308 G/A**                                                                                      GG/GA/AA                                                
  Banday 2016 \[[@B10]\]              India          Caucasian   PB                   142/184       124/18/0                150/34/0            0.167       8
  Basavaraju 2015 \[[@B11]\]          UK             Caucasian   PB                   388/495       253/117/18              309/167/19          0.543       7
  Burada 2013 \[[@B12]\]              Romania        Caucasian   PB                   144/233       115/26/3                189/42/2            0.842       8
  Garrity-Park 2008 \[[@B13]\]        USA            Mixed       HB                   114/114       52/49/13                92/20/2             0.464       8
  Gunter 2006 \[[@B14]\]              USA            Mixed       PB                   217/202       146/59/12               139/57/6            0.957       8
  Gutiérrez-Hurtado 2016 \[[@B15]\]   Mexico         Mixed       PB                   164/209       139/21/4                180/27/2            0.392       7
  Hamadien 2016 \[[@B16]\]            Saudi Arabia   Caucasian   PB                   100/100       67/23/10                59/23/18            \<0.001     8
  Jang 2001 \[[@B17]\]                Korea          Asian       PB                   27/92         24/3/0                  85/7/0              0.704       8
  Kapitanović 2014 \[[@B18]\]         Croatia        Caucasian   PB                   200/200       163/35/2                163/35/2            0.937       8
  Landi 2003 \[[@B19]\]               France         Caucasian   PB                   363/320       278/80/5                234/76/10           0.220       7
  Li 2011 \[[@B21]\]                  China          Asian       PB                   180/180       156/15/9                160/19/1            0.599       8
  Li 2017 \[[@B22]\]                  China          Asian       PB                   569/570       500/66/3                493/75/2            0.632       8
  Macarthur 2005 \[[@B23]\]           UK             Caucasian   PB                   246/389       157/74/15               224/145/20          0.577       8
  Park 1998 \[[@B25]\]                Korea          Asian       PB                   136/331       40/71/25                148/151/32          0.465       7
  Stanilov 2014 \[[@B26]\]            Bulgaria       Caucasian   PB                   119/177       88/28/3                 135/40/2            0.612       8
  Suchy 2008 \[[@B27]\]               Poland         Caucasian   PB                   350/350       254/87/9                248/95/7            0.546       8
  Theodoropoulos 2006 \[[@B28]\]      Greece         Caucasian   PB                   222/200       152/56/14               146/44/10           0.010       7
  Toth 2007 \[[@B29]\]                Hungary        Caucasian   PB                   183/141       132/48/3                111/30/0            0.157       7
  Tsilidis 2009 \[[@B30]\]            USA            Mixed       PB                   204/372       146/55/3                275/90/7            0.908       7
  Wang 2008 \[[@B31]\]                China          Asian       PB                   344/669       284/58/2                554/111/4           0.538       8
  **-857 C/T**                                                                                      CC/CT/TT                                                
  Garrity-Park 2008 \[[@B13]\]        USA            Mixed       HB                   114/114       98/16/0                 92/22/0             0.254       8
  Hamadien 2016 \[[@B16]\]            Saudi Arabia   Caucasian   PB                   100/100       85/15/0                 85/15/0             0.417       8
  Kapitanović 2014 \[[@B18]\]         Croatia        Caucasian   PB                   200/200       130/64/6                126/67/7            0.599       8
  Landi 2006 \[[@B20]\]               Spain          Caucasian   PB                   281/268       219/58/4                220/45/3            0.684       7
  Suchy 2008 \[[@B27]\]               Poland         Caucasian   PB                   350/350       253/88/9                242/98/10           0.983       8
  **-863 C/A**                                                                                      CC/CA/AA                                                
  Garrity-Park 2008 \[[@B13]\]        USA            Mixed       HB                   114/114       84/28/2                 80/33/1             0.224       8
  Suchy 2008 \[[@B27]\]               Poland         Caucasian   PB                   350/350       262/77/11               257/83/10           0.302       8
  **-1031 T/C**                                                                                     TT/TC/CC                                                
  Garrity-Park 2008 \[[@B13]\]        USA            Mixed       HB                   114/114       79/31/4                 75/36/3             0.588       8
  Kapitanović 2014 \[[@B18]\]         Croatia        Caucasian   PB                   200/200       132/56/12               135/54/11           0.082       8
  Suchy 2008 \[[@B27]\]               Poland         Caucasian   PB                   350/350       250/90/10               227/107/16          0.460       8

Abbreviations: CRC, colorectal cancer; HWE, Hardy--Weinberg equilibrium; NA, not available; NOS, Newcastle--Ottawa scale; TNF-α, tumor necrosis factor-α.

Overall and subgroup analyses {#sec3-2}
-----------------------------

To investigate potential correlations of *TNF-α* polymorphisms with the risk of CRC, 7 studies about *TNF-α* -238 G/A polymorphism (901 cases and 1179 controls), 20 studies about *TNF-α* -308 G/A polymorphism (4412 cases and 5528 controls), 5 studies about *TNF-α* -857 C/T polymorphism (1045 cases and 1032 controls), 2 studies about *TNF-α* -863 C/A polymorphism (464 cases and 464 controls) and 3 studies about *TNF-α* -1031 T/C polymorphism (664 cases and 664 controls) were enrolled for analyses. A significant association with the risk of CRC was detected for *TNF-α* -308 G/A (recessive model: *P* = 0.004, OR = 1.42, 95%CI 1.12--1.79) polymorphism in overall analyses.

Further subgroup analyses based on ethnicity of participants revealed that *TNF-α* -238 G/A was significantly correlated with the risk of CRC in Caucasians (dominant model: *P* = 0.01, OR = 0.47, 95%CI 0.26--0.86; overdominant model: *P* = 0.01, OR = 2.27, 95%CI 1.20--4.30; allele model: *P* = 0.02, OR = 0.51, 95%CI 0.29--0.90), while -308 G/A polymorphism was significantly correlated with the risk of CRC in Asians (recessive model: *P* = 0.001, OR = 2.23, 95%CI 1.38--3.63). No any other positive results were found for investigated polymorphisms in overall and subgroup analyses (see [Table 2](#T2){ref-type="table"}).

###### Overall and subgroup analyses for *TNF-α* polymorphisms and CRC

  Polymorphisms   Population   Sample size   Dominant comparison   Recessive comparison    Overdominant comparison   Allele comparison                                                    
  --------------- ------------ ------------- --------------------- ----------------------- ------------------------- ----------------------- ---------- ---------------------- ---------- -----------------------
  **-238 G/A**    Overall      901/1179      0.72                  0.94 (0.68--1.31)       0.94                      1.04 (0.34--3.20)       0.68       1.07 (0.77-1.51)       0.77       0.95 (0.70--1.31)
                  Caucasian    351/346       **0.01**              **0.47 (0.26--0.86)**   1.00                      1.00 (0.14--7.15)       **0.01**   **2.27 (1.20-4.30)**   **0.02**   **0.51 (0.29--0.90)**
                  Asian        370/762       0.31                  1.29 (0.79--2.12)       0.34                      2.69 (0.35--20.78)      0.26       0.75 (0.45--1.24)      0.38       1.24 (0.77--2.00)
  **-308 G/A**    Overall      4412/5528     0.30                  0.92 (0.78--1.08)       **0.004**                 **1.42 (1.12--1.79)**   0.84       0.99 (0.90--1.09)      0.17       0.90 (0.77--1.05)
                  Caucasian    2457/2789     0.21                  1.08 (0.96--1.22)       0.76                      1.05 (0.77--1.42)       0.15       0.91 (0.80--1.03)      0.32       1.06 (0.95--1.17)
                  Asian        4412/5528     0.27                  0.83 (0.60--1.15)       **0.001**                 **2.23 (1.38--3.63)**   0.90       1.01 (0.83--1.24)      0.16       0.81 (0.60--1.09)
  **-857 C/T**    Overall      1045/1032     0.62                  1.05 (0.86--1.28)       0.85                      0.94 (0.50--1.78)       0.66       0.95 (0.78--1.17)      0.62       1.05 (0.87--1.25)
                  Caucasian    931/918       0.85                  1.02 (0.83--1.26)       0.85                      0.94 (0.50--1.78)       0.89       0.99 (0.80--1.22)      0.82       1.02 (0.85--1.23)
  **-863 C/A**    Overall      464/464       0.50                  1.11 (0.83--1.48)       0.68                      1.19 (0.53--2.68)       0.40       0.88 (0.65--1.19)      0.64       1.06 (0.82--1.38)
  **-1031 T/C**   Overall      664/664       0.16                  1.18 (0.94--1.48)       0.58                      0.86 (0.50--1.47)       0.22       0.86 (0.68--1.09)      0.16       1.15 (0.95--1.40)
                  Caucasian    550/550       0.20                  1.18 (0.92--1.52)       0.47                      0.81 (0.45--1.44)       0.31       0.87 (0.67--1.14)      0.17       1.16 (0.94--1.44)

Abbreviations: CI, confidence interval; CRC, colorectal cancer; NA, not available; OR, odds ratio; TNF-α, tumor necrosis factor-α.

For -238 G/A, Dominant comparison: G/A + A/A vs. G/G; Recessive comparison: A/A vs. G/G + G/A; Overdominant comparison: G/G + A/A vs. G/A; Allele comparison: G vs. A.

For -308 G/A, Dominant comparison: G/A + A/A vs. G/G; Recessive comparison: A/A vs. G/G + G/A; Overdominant comparison: G/G + A/A vs. G/A; Allele comparison: G vs. A.

For -857 C/T, Dominant comparison: C/T + T/T vs. C/C; Recessive comparison: T/T vs. C/C + C/T; Overdominant comparison: C/C + T/T vs. C/T; Allele comparison: C vs. T.

For -863 C/A, Dominant comparison: C/A + A/A vs. C/C; Recessive comparison: A/A vs. C/C + C/A; Overdominant comparison: C/C + A/A vs. C/A; Allele comparison: C vs. A.

For -1031 T/C, Dominant comparison: T/C + C/C vs. T/T; Recessive comparison: C/C vs. T/T + T/C; Overdominant comparison: T/T + C/C vs. T/C; Allele comparison: T vs. C.

Sensitivity analyses {#sec3-3}
--------------------

Sensitivity analyses were carried out to examine the stability of meta-analysis results by eliminating studies that deviated from HWE. No changes of results were observed in any comparisons, which indicated that our findings were statistically reliable.

Publication biases {#sec3-4}
------------------

Potential publication biases in the current study were evaluated with funnel plots. No obvious asymmetry of funnel plots was observed in any comparisons, which suggested that our findings were unlikely to be influenced by severe publication biases.

Discussion {#sec4}
==========

To the best of our knowledge, this is so far the most comprehensive meta-analysis on correlations between *TNF-α* polymorphisms and CRC. A significant association with the risk of CRC was detected for *TNF-α* -308 G/A polymorphism in overall analyses. Further subgroup analyses based on ethnicity of participants revealed that *TNF-α* -238 G/A was significantly correlated with the risk of CRC in Caucasians, while -308 G/A polymorphism was significantly correlated with the risk of CRC in Asians. No any other positive results were found for investigated polymorphisms in overall and subgroup analyses. The stability of the synthetic results was subsequently evaluated in sensitivity analyses, and no changes of results were observed in any comparisons, which indicated that our findings were quite stable and reliable.

It is worth noting that -238 G/A and -308 G/A polymorphisms were two functional polymorphisms located in the promoter region of *TNF-α*, and the mutant alleles of these two polymorphisms were both associated with a higher expression level of *TNF-α* \[[@B10]\]. Thus, it is rational to speculate that subjects carrying mutant alleles of these two polymorphisms may have a relatively lower risk of CRC. From our results, you can see that the trends of developing CRC for these two polymorphisms in overall population are quite similar. But opposite findings were detected in further subgroup analyses. These contradictory findings in subgroup analyses may partially attribute to quite different genetics distributions of these two polymorphisms in Asians and Caucasians. Another possible explanation of this phenomenon is that genetic associations between *TNF-α* polymorphisms and CRC may also be influenced by gene-gene and gene-environmental interactions, but the extent of impact of gene--gene and gene--environmental interactions on genetic association between *TNF-α* polymorphisms and CRC in different ethnicities may be different.

As for evaluation of heterogeneities, obvious between-study heterogeneities were detected for -308 G/A polymorphisms in certain comparisons (data not shown). In further stratified analyses, a great reduction in heterogeneity was found in the Asian subgroup. However, the reduction tendency of heterogeneity in Caucasians was not obvious. These findings suggested that differences in ethnic background could partially explain observed heterogeneities between studies.

As with all meta-analysis, the present study certainly has some limitations. First, our results were based on unadjusted estimations due to lack of raw data, and failure to perform further stratified analyses according to age, gender and co-morbidity conditions may affect the reliability of our findings \[[@B34],[@B35]\]. Second, only case-control studies were included in this meta-analysis, and thus our findings may also be influenced by potential selection bias \[[@B35],[@B36]\]. Third, associations between *TNF-α* polymorphisms and CRC may also be influenced by gene-gene and gene-environmental interactions. However, the majority of studies did not consider these potential interactions, which impeded us to perform relevant analyses accordingly \[[@B37],[@B38]\]. Taken these limitations into consideration, the results of the current study should be interpreted with caution.

Overall, our meta-analysis suggested that *TNF-α* -238 G/A polymorphism may serve as a potential biological marker for CRC in Caucasians, and *TNF-α* -308 G/A polymorphism may serve as a potential biological marker for CRC in Asians. However, further well-designed studies are warranted to confirm our findings. Additionally, future investigations are needed to explore potential roles of other *TNF-α* polymorphisms in the development of CRC.
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